Blood Test Distinguishes Alcohol-Related Liver Damage from Fatty Liver Disease

Got story updates? Submit your updates here. ›

Fatty liver disease, affecting nearly one in three adults globally, presents a significant health challenge. Often linked to metabolic conditions like obesity and diabetes, or excessive alcohol consumption, accurately pinpointing the cause - alcohol-related liver damage versus metabolic dysfunction - can be surprisingly difficult in routine medical care. Now, the MAPI, a new blood test developed at the University of California San Diego, utilizes five standard lab values to estimate the likelihood that alcohol-related liver disease is contributing to a patient's condition, even when alcohol consumption is underreported.

Why it matters

Undiagnosed alcohol-related damage can silently progress for years, leading to preventable hospitalizations and fatalities. The MAPI is designed to guide clinicians on when to pursue more specific alcohol testing, such as phosphatidylethanol (PEth), which is highly accurate but less accessible. Accurately distinguishing between alcohol-related liver damage and metabolic causes is crucial for providing appropriate treatment and preventing further progression of the disease.

The details

The MAPI was evaluated on over 500 adults in the San Diego area and approximately 1,800 individuals in Sweden. Results, published in Gastroenterology, demonstrated that the MAPI outperformed commonly used blood tests in distinguishing between alcohol-related liver damage and metabolic causes. The MAPI represents a step forward in the broader trend toward more precise and personalized approaches to managing fatty liver disease, including the development of non-invasive biomarkers, the use of artificial intelligence and machine learning, new pharmacological treatments, and the expansion of telemedicine and remote monitoring.

• The MAPI was developed at the University of California San Diego.
• The MAPI was evaluated on over 500 adults in the San Diego area and approximately 1,800 individuals in Sweden.
• The results of the MAPI evaluation were published in Gastroenterology in 2026.

What’s next

Researchers continue to explore the potential of proteomics and other non-invasive biomarkers to further improve the accuracy of diagnosing the underlying cause of fatty liver disease. Additionally, ongoing clinical trials are investigating new pharmacological treatments targeting different aspects of the disease process.